Introduction:Currently there are only a limited number of drugs available for treatment of androgenetic alopecia and telogen effluvium. However, certain plants and their standardized extracts may provide some clinical benefits against hair loss. We formulated a herbal shampoo and a solution to evaluate their efficacy, safety, and synergy in hair loss. Methods: We conducted a randomized, placebo-controlled, single-blind, clinical and instrumental study for 6 months on 120 subjects with androgenetic alopecia and telogen effluvium, confirmed by pull test and phototricogram. Each subject was examined monthly. At the end of the study, a self-assessment test was carried out. Results: Herbal formulations were found to be more effective in preventing and reducing hair loss than placebo at every assessment point. Anagen/telogen ratios improved significantly in the study group. In addition, concomitant use of the shampoo and solution were found to be more effective than single product use. Conclusion: We interpret this eutrophic effect for scalp hair as the final outcome of the entire content of our herbal formula, which has antiandrogenic, anti-inflammatory, antioxidative, angiogenic, and hair-stimulating features. In combination, these features help prevent hair from falling out and reducing hair loss.
Topical Fc leaf extract may be beneficial for some inflammatory disorders and androgen-dependent disorders of the skin such as androgenetic alopecia.
Vitiligo is a pigment disease characterized by the disruption of melanocyte structure and function. Its etiology is unknown; however, genetic predisposition, biochemical factors, and neural mechanisms are thought to be effective. Although many agents are being used for its treatment, generally there is no absolute cure. The aim of the present study is to evaluate the effectiveness of topical Nigella sativa seed oil on vitiligo patients. Thirty‐three vitiligo patients were included in the study. Totally 47 areas were evaluated in all patients. Cream containing N sativa seed oil was topically applied to hands, face, and genital region two times a day for 6 months. Statistically significant repigmentation was detected in hands, face, and genital region, the three treatment areas, and the p values are found .005, .001, and .004, respectively. N sativa can be used as an adjuvant therapy that can contribute to the treatment especially in sensitive skin areas like genital region.
Lepidium sativum L. (Brassicaceae) (Ls), garden cress, is an edible herb that is botanically related to watercress and mustard, sharing their peppery, tangy flavor and aroma. The various parts of the plant have been traditionally used for many respiratory, rheumatologic, cardiovasculary, metabolic, and gastrointestinal disorders. Several studies were performed showing its antiinflammatory, anticarcinogenic, antiproliferative as well as tissue protective effects. In all of these studies the positive effects of Ls were concluded as the result of its antioxidant features due to the polyphenols and organosulphur compounds. In this study, we investigated the molecular basis of antiinflammatory, antiproliferative, antimitotic and antiandrogenic effects of Ls leaf extract in HaCaT cells. The gene expression levels of vascular endothelial growth factor (VEGF), tumor necrosis factoralpha (TNF-α), interleukin 1-alpha (IL-1α), and 5 alpha-reductase type II (SRD5A2) were studied. Gene expressions were determined by RT-qPCR analysis. Fold change results of the gene expression analyses showed that the plant extract caused statistically significant downregulation of VEGF (0.2167, p<0.0001), p = 0.0262), and SRD5A2 (0.0567, p<0.0001). The fold change for IL-1α was 0.6900 and this result was not statistically significant (p = 0.1522). These preliminary results may partially explain the clinical success of Ls in the traditional medicine. Considering these results, topical application of Lepidium sativum extract may be beneficial for inflammatory, androgen dependent disorders of the skin.
BackgroundCurrently while, topical minoxidil and oral finasteride are the only medications approved in androgenetic alopecia (AGA), the cause oriented treatment and immunsupressive treatment are being performed in telogen effluvium (TE) and alopecia areata (AA) respectively. Considering the inflammatory factors in the pathogenesis of these three nonscarring alopecia forms, we have formulated a mixture for topical usage composed of six different herbal extracts (HE) which have already known antiinflammatory and antioxidant features.Materials and MethodsIn addition to performing the phytochemical analysis of HE, we detected the gene expression level of IL-1α, the crucial hair loss mediator, for the putative efficacy in nonscarring alopecia. Cell proliferation assay was performed by XTT reagent. After determination of non-cytotoxic concentration, HaCaT cells were treated with HE. RNA isolations were carried out from both non-treated and treated cell groups by using TRI-reagent. Gene expressions of IL-1α and as control GAPDH were determined by RT-qPCR analysis.ResultsResults were represented as “IL-1α/GAPDH Fold Change”. HE solution caused statistically significant downregulation of IL-1α gene expressions (p<0.0001), compared to untreated control cells. HE treatment ended up with 0.1900 fold change for IL-1α.ConclusionIL-1α is a direct growth inhibitory agent in hair follicles and an important actor in the pathogenesis of AGA , TE, and AA. Considering together the vitamins, flavonoids, and trace elements identified in the phytochemical analyses and downregulation of IL-1α in HaCaT cells, our HE may be an auxiliary agent in the therapy of these three nonscarring alopecia forms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.